On-Demand Webinars

  1. Viral Clearance Strategies For Monoclonal Antibodies And Proteins 1/30/2026

    Guidance on designing viral clearance studies using regulatory-aligned, risk‑based strategies, optimized assays, and real case examples for safe, efficient biologics development.

  2. Fast-Track Innovation, Address CMC Challenges In Expedited Pathways 1/26/2026

    Learn to overcome solubility challenges and utilize flexible development strategies to transition innovative treatments from early-phase trials to commercialization while ensuring patient safety.

  3. Drug Product Development: Preclinical To Commercial 1/26/2026

    Watch a unified roadmap for drug product development, outlining phase‑appropriate studies, QTTP importance, and key requirements from preclinical stages through commercialization.

  4. Understanding Surfactant Excipients In Biologic Formulations 1/26/2026

    Uncover surfactant characterization, polysorbate degradation, and advanced analytics, such as multidimensional LC, to strengthen stability assessment and formulation for biologics and advanced therapies.

  5. Subvisible Particle Analysis For End‑To‑End Quality 1/26/2026

    See strategies for precise subvisible particle analysis, covering regulatory expectations, method validation, and controlling variability when transitioning workflows from R&D to GMP environments.

  6. Building A Path To A Successful AAV Product 1/26/2026

    See state‑of‑the‑art analytical methods for AAV characterization, key quality attributes to monitor, and approaches for measuring infectivity and full‑to‑empty capsid ratios.

  7. Lyo‑Modelling For Risk Reduction And Process Insights 1/26/2026

    Use lyophilization modelling to optimize freeze‑drying, boost product quality, and lower commercialization risks through predictive insights, robustness analysis, and deeper process understanding.

  8. Detecting Particles In Biologic And CGT Drug Products 1/26/2026

    Identify and characterize visible and subvisible particles that can form during biologic and cell or gene therapy development.

  9. Developability Assessment And Early Formulation Studies 1/26/2026

    Early developability and pre‑formulation screening build strong biophysical data, reduce late‑stage risks, support candidate selection, and streamline biologics development toward clinical success.

  10. AUC As An Alternative For Biologics, Gene Therapy Characterization 1/26/2026

    Learn how Analytical Ultracentrifugation enables detailed characterization of biologics, vaccines, and gene therapy vectors, offering a powerful alternative for R&D and emerging QC needs.